These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23331082)

  • 1. Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens.
    Fischer NO; Rasley A; Corzett M; Hwang MH; Hoeprich PD; Blanchette CD
    J Am Chem Soc; 2013 Feb; 135(6):2044-7. PubMed ID: 23331082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immobilization of His-tagged proteins on nickel-chelating nanolipoprotein particles.
    Fischer NO; Blanchette CD; Chromy BA; Kuhn EA; Segelke BW; Corzett M; Bench G; Mason PW; Hoeprich PD
    Bioconjug Chem; 2009 Mar; 20(3):460-5. PubMed ID: 19239247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic analysis of his-tagged protein binding to nickel-chelating nanolipoprotein particles.
    Blanchette CD; Fischer NO; Corzett M; Bench G; Hoeprich PD
    Bioconjug Chem; 2010 Jul; 21(7):1321-30. PubMed ID: 20586461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.
    Uppada SB; Bhat AA; Sah A; Donthamshetty RN
    Vaccine; 2011 Nov; 29(50):9352-60. PubMed ID: 22001881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis.
    Fischer NO; Infante E; Ishikawa T; Blanchette CD; Bourne N; Hoeprich PD; Mason PW
    Bioconjug Chem; 2010 Jun; 21(6):1018-22. PubMed ID: 20509624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
    Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
    Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
    Saluja V; Visser MR; Ter Veer W; van Roosmalen ML; Leenhouts K; Hinrichs WL; Huckriede A; Frijlink HW
    Vaccine; 2010 Nov; 28(50):7963-9. PubMed ID: 20946860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-mediated immune response to epitopic MAP (multiple antigen peptide) construct of LcrV antigen of Yersinia pestis in murine model.
    Shreewastav RK; Ali R; Uppada JB; Rao DN
    Cell Immunol; 2012; 278(1-2):55-62. PubMed ID: 23121976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platycodin d improves the immunogenicity of newcastle disease virus-based recombinant avian influenza vaccine in mice.
    Xie Y; Sun HX; Li D
    Chem Biodivers; 2010 Mar; 7(3):677-89. PubMed ID: 20232336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
    Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
    Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of nanolipoprotein particles (NLPs) as an in vivo delivery platform.
    Fischer NO; Weilhammer DR; Dunkle A; Thomas C; Hwang M; Corzett M; Lychak C; Mayer W; Urbin S; Collette N; Chiun Chang J; Loots GG; Rasley A; Blanchette CD
    PLoS One; 2014; 9(3):e93342. PubMed ID: 24675794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attachment of LcrV from Yersinia pestis at dual binding sites to human TLR-2 and human IFN-gamma receptor.
    Abramov VM; Khlebnikov VS; Vasiliev AM; Kosarev IV; Vasilenko RN; Kulikova NL; Khodyakova AV; Evstigneev VI; Uversky VN; Motin VL; Smirnov GB; Brubaker RR
    J Proteome Res; 2007 Jun; 6(6):2222-31. PubMed ID: 17441749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of size on particulate vaccine adjuvants.
    Shah RR; O'Hagan DT; Amiji MM; Brito LA
    Nanomedicine (Lond); 2014 Dec; 9(17):2671-81. PubMed ID: 25529570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
    Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
    Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L
    Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs.
    Robuccio JA; Griffith JW; Chroscinski EA; Cross PJ; Light TE; Lang CM
    Lab Anim Sci; 1995 Aug; 45(4):420-6. PubMed ID: 7474883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system.
    Moyle PM; Hartas J; Henningham A; Batzloff MR; Good MF; Toth I
    Nanomedicine; 2013 Oct; 9(7):935-44. PubMed ID: 23428988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant.
    Chaitra MG; Nayak R; Shaila MS
    Vaccine; 2007 Oct; 25(41):7168-76. PubMed ID: 17709160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.